Get the Stockscreener App
1.45
0.68%
-0.01
After Hours:
1.45
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen stock touches 52-week low at $1.54 amid market challenges - MSN
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 - MSN
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN
SG Americas Securities LLC Grows Stock Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.31 amid market challenges - MSN
ABOS stock touches 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - cnhinews.com
JPMorgan Chase & Co. Has $156,000 Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.52 amid market challenges - Investing.com India
ABOS stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares - MarketBeat
Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN
Analysts Set Expectations for ABOS FY2025 Earnings - Defense World
Acumen Pharmaceuticals CFO sells shares totaling $56,619 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com - Investing.com Canada
Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC - Defense World
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1% - Defense World
Acumen stock touches 52-week low at $1.54 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian
Acumen's Alzheimer's Drug Shows Promise: Phase 1 Trial Reveals Strong Safety Profile, Plaque Reduction - StockTitan
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Purchased by Geode Capital Management LLC - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Bought by Barclays PLC - Defense World
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock - Investing.com India
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in Stock - MarketBeat
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals’ chief legal officer sells $20,505 in stock By Investing.com - Investing.com Nigeria
0.81%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):